These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28274743)

  • 1. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.
    York ER; Varella-Garcia M; Bang TJ; Aisner DL; Camidge DR
    J Thorac Oncol; 2017 Jul; 12(7):e85-e88. PubMed ID: 28274743
    [No Abstract]   [Full Text] [Related]  

  • 2. First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC.
    Ancevski Hunter K; Friedland DM; Villaruz LC; Burns TF
    J Thorac Oncol; 2018 Jan; 13(1):e3-e5. PubMed ID: 28989039
    [No Abstract]   [Full Text] [Related]  

  • 3. Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.
    Kang J; Chen HJ; Wang Z; Liu J; Li B; Zhang T; Yang Z; Wu YL; Yang JJ
    J Thorac Oncol; 2018 Apr; 13(4):e49-e53. PubMed ID: 29128427
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.
    Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG
    Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
    Stratmann JA; Michels S; Hornetz S; Christoph DC; Sackmann S; Spengler W; Bischoff H; Schäfer M; Alt J; Müller A; Laack E; Kimmich M; Griesinger F; Sebastian M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2457-2463. PubMed ID: 30244389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE approves osimertinib for advanced lung cancer.
    Burki TK
    Lancet Respir Med; 2016 Dec; 4(12):954. PubMed ID: 27814987
    [No Abstract]   [Full Text] [Related]  

  • 7. Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.
    Cheng Y; Yu Q; Xiong Y; Guo C; Nie L
    Thorac Cancer; 2021 Mar; 12(5):690-692. PubMed ID: 33438350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
    Soejima K; Yasuda H; Hirano T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.
    Chen K; Zhou F; Shen W; Jiang T; Wu X; Tong X; Shao YW; Qin S; Zhou C
    J Thorac Oncol; 2017 Jun; 12(6):e65-e68. PubMed ID: 28093244
    [No Abstract]   [Full Text] [Related]  

  • 11. EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Dearden S; Brown H; Jenkins S; Thress KS; Cantarini M; Cole R; Ranson M; Jänne PA
    Lung Cancer; 2017 Jul; 109():9-13. PubMed ID: 28577957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    Gortais H; Daniel C; Bidard FC; Jeannot E; Callens C; Cabel L
    J Thorac Oncol; 2017 Sep; 12(9):e138-e139. PubMed ID: 28838712
    [No Abstract]   [Full Text] [Related]  

  • 13. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
    Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Osimertinib in Choroidal Metastases from EGFRmt T790M-Positive Non-Small Cell Lung Adenocarcinoma.
    Dall'Olio FG; Ruatta C; Melotti B; Sperandi F; Ciardella AP; Ardizzoni A
    J Thorac Oncol; 2017 Oct; 12(10):e165-e167. PubMed ID: 28939150
    [No Abstract]   [Full Text] [Related]  

  • 15. A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
    Pinquie F; Cortot AB; Chevalier LM; Morel A; Sandrini J; Guguen C; Morvan B; Molinier O
    Clin Lung Cancer; 2022 Mar; 23(2):e131-e134. PubMed ID: 34548228
    [No Abstract]   [Full Text] [Related]  

  • 16. Osimertinib effective in EGFR T790M-positive lung cancer.
    Mayor S
    Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
    Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
    Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
    Sullivan I; Planchard D
    Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
    Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA
    J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
    Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
    Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.